Two healthcare plans have joined the ranks of those suing Big Pharma heavyweights over their alleged contributions to the national opioid crisis that has devastated the nation.
Another lawsuit has been filed against a group of pharma companies and distributors that claims their allegedly deceptive marketing of opioids has resulted in ER physicians being paid little to no compensation for providing opioid-related treatment.
A proposed class action claims 14 pharmaceutical companies' and wholesale distributors' allegedly deceptive marketing of opioids has led to what public health officials are calling 'the worse drug crisis in American history.'
Another proposed class action filed on behalf of children born with Neonatal Abstinence Syndrome accuses a group of pharmaceutical companies and distributors of contributing to the 'opioid epidemic' that has swept across the state of Louisiana.
Another proposed class action filed on behalf of a minor child diagnosed with NAS has been added to the multidistrict litigation involving pharmaceutical companies’ and distributors’ alleged contributions to the country’s growing 'opioid epidemic.'
A growing number of lawsuits have been filed against a group of pharmaceutical companies and distributors over claims that the defendants have caused a national health crisis by deceptively marketing opioids for long-term use.
A group of 20 pharmaceutical companies and distributors has been named in a proposed class action lawsuit filed on behalf of a newborn baby who the suit claims suffers from neonatal abstinence syndrome (NAS) as a result of the defendants’ actions.
A group of pharmaceutical companies is facing a proposed class action lawsuit that claims the defendants, since the 1990s, have misled doctors and patients regarding the risks associated with using opioids to treat chronic pain.
Three Mississippi hospitals claim the conduct of 19 pharma-industry heavyweights contributed greatly to the nation's opioid abuse epidemic.
Another proposed class action has been filed against various pharmaceutical companies and distributors, claiming the defendants’ deceptive marketing of opioid products has contributed to their widespread abuse.